Le Lézard
Classified in: Covid-19 virus
Subject: Lawsuit

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Talis Biomedical Corporation (TLIS) Investors and Encourages Investors to Contact the Firm Before March 8, 2022

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ: TLIS) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's February 2021 initial public offering ("IPO" or the "Offering"). Investors have until March 8, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Talis develops diagnostic tests to enable accurate, reliable, low cost, and rapid molecular testing for infectious diseases and other conditions at the point-of-care. The Talis One tests are being developed for respiratory infections, infections related to women's health, and sexually transmitted infections.

On February 12, 2021, the Company filed its prospectus on Form 424B4 with the SEC, which forms part of the Registration Statement. In the IPO, the Company sold 15,870,000 shares of common stock at a price of $16.00 per share. The Company received net proceeds of approximately $232.6 million from the Offering. The proceeds from the IPO were purportedly to be used for commercial activities (including the hiring and training of sales and marketing personnel), research and development, and working capital and other general corporate purposes.

On March 8, 2021, Talis announced that it had withdrawn its Emergency Use Authorization ("EUA") application for the Talis One COVID-19 test. In a press release, the Company revealed that "[i]n late February, the FDA informed the company that it cannot ensure the comparator assay used in the primary study has sufficient sensitivity to support Talis's EUA application." As a result, Talis "intends to initiate its previously planned clinical validation study in a point-of-care environment" to submit its EUA application "early in the second quarter of 2021." This study "was designed with a different comparator assay, which Talis believes will address the FDA's concerns." On this news, the Company's stock price declined by $1.80 per share, or approximately 12.29%, from $14.65 per share to close at $12.85 per share on March 8, 2021.

Then, on August 10, 2021, Talis revealed that its "development timelines have been extended by delays in the launching of [Talis's] COVID-19 test and manufacturing scale." As a result, Talis "expect[s] to see [its] first meaningful revenue ramp in 2022." On this news, the Company's stock price declined by $0.58 per share, or approximately 6.47%, from $8.97 per share to close at $8.39 per share on August 11, 2021.

On August 30, 2021, after the market closed, Talis announced that its Chief Executive Officer ("CEO"), Brian Coe, had "stepped down" as President, CEO, and Director. On this news, the Company's stock price declined by $1.00 per share, or approximately 11.04%, from $9.06 per share to close at $8.06 per share on August 31, 2021.

On November 15, 2021, Talis announced that Brian Blaser was appointed as President, CEO, and Director of Talis effective December 1, 2021. However, a week after his appointment, on December 8, 2021, Talis announced that Brian Blaser had stepped down from his positions. On this news, the Company's stock price declined by $0.55 per share, or approximately 11.39%, from $4.83 per share to close at $4.28 per share on December 8, 2021.

The lawsuit alleges that the Registration Statement was false and misleading and omitted to state material adverse facts. Specifically, Defendants failed to disclose to investors that: (1) the comparator assay in the primary study lacked sufficient sensitivity to support Talis's EUA application for Talis One COVID-19 test; (2) as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) as a result, the Company's commercialization timeline would be significantly delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Talis securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

These press releases may also interest you

at 19:40
Ahead of the 75th World Health Assembly (WHA) on May 22-28 in Switzerland, AIDS Healthcare Foundation (AHF) calls on WHA Member States to commit to the adoption of a new Global Public Health Convention ? a binding agreement that would ensure complete...

at 19:20
The Global Financing Facility (GFF) and PAI announced today a new collaboration to further strengthen civil society and youth engagement in GFF partner countries to help deliver better health for all women, children and adolescents, as part of the...

at 19:00
BEST Inc. ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China, today released its environmental, social, and governance (ESG) report for 2021. The report presents an overview of the...

at 19:00
Uplift Education implemented Rhithm, Inc's application this school year for students. It is an easy-to-use mental health wellness check-in tool that allows educators to proactively shape the culture of a classroom, and school daily during...

at 18:51
Majestic Water Spouts is a sheet metal manufacturer focusing on water feature products sold and distributed across the globe.  We are proud to announce today that Majestic Water Spouts was named the winner of The 2022 ASU Sun Devil 100 - Fastest...

at 18:35
Linamar Corporation today announced the formation of Linamar MedTech, a new medical manufacturing group which will focus on leveraging its expert capabilities in precision manufacturing to pursue opportunities in the Medical Device and Precision...

News published on 21 january 2022 at 16:45 and distributed by: